The interest of many investigators has been concentrated mainly on ways to activate and maintain those effector cells of adaptive immunity that are believed be the major actors in eliminating the tumor cells, the CD8+ cytolytic T cells (CTL). The gene discussed is CD8A; the disease is neoplasm.